Baby breathing treatment: gene test may end guesswork for albuterol in bronchiolitis

NCT ID NCT06946264

Recruiting now Knowledge-focused Sponsor: Nemours Children's Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a common asthma drug, albuterol, helps babies with bronchiolitis (a lung infection). Researchers will give 400 children either albuterol or a placebo and check their breathing. They will also collect DNA samples to see if certain genes predict who gets better. The goal is to create a tool that helps doctors decide when to use this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Albuterol (a bronchodilator drug given as a mist)
What this could lead to: If successful, this could lead to a simple test to predict which children with bronchiolitis will benefit from albuterol, reducing unnecessary treatments and improving care.
What could go wrong: This is an early-stage study focused on finding genetic markers, not proving a cure. The results may not lead to immediate changes in treatment, and the genetic links may be weak or not generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiolitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIOLITIS BRONCHODILATOR AGENTS

Contacts and locations

Locations

Nemours Children's Health
RECRUITING

Orlando, Florida, 32827, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.